Measures involving body weight      


Select table page: First Prev 1 - 10 / 311 (311) Next Last
    Access protocols via the Procedure column.
Sort/
Pick
Data set
Procedure / Protocol
Treatment
Phenotype Measure / Variable (click to view)
Panel
No. of Strains
Sex
Age
Sample Size (Avg)
Year
Ankra-Badu1 body weight (none) weight at week 3   [g]  WK3   21202 QTL population both 3wks N=502 2009
Ankra-Badu1 body weight (none) weight at week 6   [g]  WK6   21203 QTL population both 6wks N=502 2009
Ankra-Badu1 body weight (none) weight at week 10   [g]  WK10   21204 QTL population both 10wks N=502 2009
Ankra-Badu1 body weight (none) weight gain from 3-6 weeks   [g]  EARLY   21214 QTL population both 6wks N=502 2009
Ankra-Badu1 body weight (none) weight gain from 6-10 weeks   [g]  LATE   21215 QTL population both 10wks N=502 2009
Ankra-Badu1 body weight (none) empty body weight   [g]  EBW   21216 QTL population both 10wks N=502 2009
    Attie2 body weight high-fat high-sucrose diet body weight after diet   [g]  bw   110632     wk:    1    2    3    4    5    6    7    8    9    10    11    12    13    14    15    16    17    (5 more)... DO population both 5-26wks N=250 2018
    Attie2 body weight high-fat high-sucrose diet change in body weight after diet (compared to wk 1)   [g]  bw_chg   110654     wk:    2    3    4    5    6    7    8    9    10    11    12    13    14    15    16    17 DO population both 6-21wks N=250 2018
    Attie2 body weight high-fat high-sucrose diet change in body weight after diet (compared to wk 10), wk 17   [g]  bw_chg_wk17v10   110670     DO population both 21wks N=236 2018
    Attie2 body weight high-fat high-sucrose diet body weight at time of oral glucose tolerance test (~14 wks on diet)   [g]  bw_oGTT   110705     DO population both 18wks N=248 2018
    All boxes             To see more rows use the paging control at top.






Other available data sets:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
ITP1 body weight
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate
Various interventions vs. controls. UM-HET3 population both various 2004-2024